A rigorous validation study of more than 50 potential markers for detecting early signs of ovarian cancer in blood has found that the most accurate marker is CA-125, a protein that is already routinely monitored in women with the disease. Panels of markers tested in the study offered, at best, only marginal improvements in the ability to detect the disease over CA-125 alone. Read more > >
-
In mice, adding tigatuzumab to gemcitabine eliminated tumor-initiating cells
-
Dimethyl-celecoxib inhibits both tumors and supporting vasculature
-
Experimental device uses a microfilter to detect circulating tumor cells
-
Disruptions to the immune system may be early signs of the disease
-
Physicians should be aware of the risk of another cancer among these long-term survivors
The Director’s Update for this issue is an abridged version of the remarks delivered by NCI Director Dr. John E. Niederhuber on Monday, April 20, at the 100th Annual Meeting of the American Association for Cancer Research in Denver. Read more > >
The chief executive officer of the American Association for Cancer Research shares her thoughts about past accomplishments and future efforts in cancer research Read more > >
Special Issue on Bioinformatics
Don’t miss our May 5 special issue on bioinformatics, which will highlight recent meetings, progress on electronic health records, research advances, and resources for those who are looking to collaborate or secure project funding.
NCI Cancer Bulletin special issues are some of the most popular among our readers. Past special issues have focused on childhood cancers, personalized drug development, and cancer imaging.
-
Clinical research staff from Meharry Medical College enrolled a majority of eligible patients at Nashville General Hospital
-
Findings from two recent animal model studies raise concerns about testing these agents in patients with early stage disease
-
The Memorial Sloan-Kettering oncologist has made integral contributions to kidney cancer treatment during his 20-year career
-
Can highly conformal radiotherapy stop or delay the spread of metastatic cancer?
-
- New Stem Cell Guidelines Proposed by NIH
- GSK Seeks Approval for HPV Vaccine
- Fraumeni Receives AACR Lifetime Achievement Award
- Barker Receives AACR Margaret Foti Award
- NCI Chief Operating Officer Lawrence Ray Retiring
- NCI Lecture Series Features Dr. Julie Overbaugh
- Cancer.gov Streamlines Clinical Trials Search Process
- New Resources on Cancer Health Disparities Research Available
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.
